Aug. 8 at 4:31 PM
$RGNX Rando has mentioned this up before, but I think it would make sense for Regenx to use the 121 PRV to shorten the 314 BLA review from 12 months to 6 months. Their current cash will last until Q4 2027 and there's other potential milestone payments and options that can push the cash runway into 2028.
Additional Funding:
Nippon Shinyaku milestone for 121 approval:
$40 million
Second
$100 million from AbbVie in 2027
314 BLA submission milestone: amount not disclosed
314 BLA approval milestone: amount not disclosed, but if 121 PRV were to be used this would hit mid 2027
PRV from 202 Approval: Potentially
$150-
$200 million in 2H 2027
50% of 121 PRV from AbbVie:
$75 -
$100 million
Healthcare Royalty:
$50 million available if certain sales threshold hit by Dec 31st, 2026 and another
$50 million option available in 2027.
Overall pulling up the commercial launch of 314 by 6 months would be huge and if things go well they could have both 202 and 314 on the market in Q3 2027 generating revenue.
